10-Q: Coeptis Therapeutics Holdings Reports Third Quarter 2024 Results, Focuses on Strategic Growth

Coeptis Therapeutics Holdings reported its third quarter 2024 results, highlighting ongoing product development and strategic partnerships while navigating financial challenges.

Summary

• Coeptis Therapeutics Holdings, Inc. reported its financial results for the quarter ended September 30, 2024.
• The company is focused on developing its product portfolio and exploring strategic partnerships in areas like auto-immune disease and oncology.
• The company's net loss for the nine months ended September 30, 2024, was $7,865,647, compared to a net loss of $17,510,948 for the same period in 2023.
• Operating expenses decreased significantly from $18,125,156 in the first nine months of 2023 to $7,892,274 in the same period of 2024, primarily due to lower professional service expenses.
• The company's cash and cash equivalents decreased from $1,469,134 at the end of 2023 to $1,137,453 as of September 30, 2024.
• Coeptis has an accumulated deficit of $95,221,907 as of September 30, 2024, raising concerns about its ability to continue as a going concern.
• The company is actively seeking additional capital through equity or debt financing to support its operations and business plans.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in product development and strategic partnerships, the company's financial situation is concerning with significant losses, low cash reserves, and debt defaults. The need for additional capital raises uncertainty about the company's future.

Positives

• The company's net loss has significantly decreased year-over-year, indicating improved financial performance.
• Operating expenses have been substantially reduced, reflecting cost-cutting measures.
• The successful Series A preferred stock offering has brought in new capital.
• The company has made progress in its strategic partnerships and product development efforts.
• The company has received a Class II designation for its CD38-Diagnostic from the FDA.

Negatives

• The company has an accumulated deficit of $95,221,907, raising concerns about its long-term financial viability.
• Cash and cash equivalents have decreased to $1,137,453, indicating a need for additional funding.
• The company has minimal revenue and is not expected to generate significant revenue for at least the next two years.
• Several notes payable are in default as of September 30, 2024.
• The company has a history of losses and has not yet achieved sustained profitable operations.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• There is a risk that the company may not be successful in developing and commercializing its products.
• The company faces challenges in managing its debt obligations and may experience further defaults.
• The company's reliance on strategic partnerships and collaborations exposes it to risks associated with those relationships.
• The company's investments in privately held companies are subject to impairment risk.

Future Outlook

The company plans to continue its product development efforts, explore strategic partnerships, and seek additional capital to support its operations and business plans. Management does not expect the Company to generate any significant revenue for at least the next two years.

Management Comments

• Management believes that additional financing as necessary will result in improved operations and cash flow.
• Management is focused on identifying and investing resources into innovative products and technologies.
• Management believes that the ability to raise capital through equity transactions will increase liquidity and enable the execution of managements operating strategy.

Industry Context

The company operates in the competitive pharmaceutical and biotechnology industries, focusing on innovative therapies in areas like oncology and auto-immune diseases. The company is leveraging strategic partnerships and technology platforms to develop novel treatments. The company is also navigating the challenges of operating as a smaller public company with limited resources.

Comparison to Industry Standards

• Coeptis's financial performance, particularly its net losses and cash burn, is not uncommon for early-stage biotech companies focused on research and development.
• Compared to companies like Celldex Therapeutics (CLDX) or Atara Biotherapeutics (ATRA), which are also developing cell-based therapies, Coeptis is at an earlier stage of development and has a smaller market capitalization.
• The company's reliance on external funding through equity and debt is typical for companies in this sector, but the high level of debt and defaults are concerning.
• The company's focus on strategic partnerships and licensing agreements is a common strategy in the biotech industry to leverage external expertise and resources.
• The company's development of the GEAR-NK platform and CD38-Diagnostic tool aligns with the industry trend towards personalized medicine and targeted therapies.

Related Party Transactions

• The company entered into an unsecured note agreement with a related party in the principal amount of $500,000.
• The company entered into a transaction with AG Bio Life Capital I LP, where an employee of the Company is the general partner.

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential capital raises.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers and partners may be affected by the company's ability to develop and commercialize its products.
• Creditors face the risk of non-payment due to the company's debt defaults.

Next Steps

• The company will continue to develop its product portfolio and explore strategic partnerships.
• The company will seek additional capital through equity or debt financing.
• The company will continue to assess market opportunities, intellectual property protection, and potential regulatory strategies for the CD38 Assets.
• The company anticipates holding the final closing of its Series A preferred stock offering in or around November 2024.

Key Dates

Keywords

Pharmaceutical, Biotechnology, Therapeutics, Oncology, Auto-immune, CD38, GEAR-NK, SNAP-CAR, Cell Therapy, Warrants, Preferred Stock, Clinical Trials, Licensing, Debt, Capital Raise